Is Mounjaro Approved for PCOS? UK Regulatory Status Explained

Polycystic ovary syndrome affects approximately 1 in 10 women of reproductive age in the United Kingdom, making it one of the most common hormonal disorders encountered in clinical practice. With the recent surge of interest in GLP-1 receptor agonist medications like Mounjaro (tirzepatide), many women living with PCOS are understandably curious about whether this medication might offer them a new treatment avenue for managing their symptoms and improving their quality of life.

Quick Summary

Mounjaro (tirzepatide) is not currently approved specifically for PCOS treatment in the UK, though it may be prescribed off-label by healthcare professionals for women with PCOS who also meet the criteria for type 2 diabetes or weight management treatment.

• Mounjaro is licensed in the UK only for type 2 diabetes management and chronic weight management
• The MHRA has not granted approval for PCOS as a standalone indication
• Off-label prescribing may occur when women with PCOS also have obesity or diabetes
• Clinical research is ongoing to investigate tirzepatide's effects on PCOS symptoms
• Women with PCOS should consult their GP or endocrinologist before considering Mounjaro

Table of Contents

• Understanding Mounjaro's Current UK Regulatory Status
• The Connection Between PCOS, Insulin Resistance and GLP-1 Medications
• Off-Label Prescribing: When Mounjaro May Be Considered for PCOS
• Clinical Evidence for Tirzepatide in PCOS Management
• NICE-Approved Treatments for PCOS in the UK
• Future Developments and Ongoing Research

Understanding Mounjaro's Current UK Regulatory Status

When we talk about medication approvals in the United Kingdom, we need to understand the role of the Medicines and Healthcare products Regulatory Agency, commonly known as the MHRA. This independent body is responsible for ensuring that all medicines available in the UK meet strict standards of safety, quality, and effectiveness before they can be prescribed to patients.

Mounjaro, which contains the active ingredient tirzepatide, received its initial UK approval in September 2023 for the treatment of type 2 diabetes mellitus in adults. Subsequently, it gained approval for chronic weight management in adults with a BMI of 30 or above, or those with a BMI of 27 or above who have at least one weight-related health condition. However, and this is the crucial point for anyone interested in using it for PCOS, the medication has not received regulatory approval specifically for polycystic ovary syndrome treatment.

The distinction between approved indications and off-label use is fundamental to understanding your options as a patient. When a medication is approved for a specific condition, it means that clinical trials have demonstrated sufficient evidence of safety and efficacy for that particular use. The manufacturer has submitted this evidence to the MHRA, and the regulator has agreed that the benefits outweigh the risks for that specific patient population.

• MHRA approval requires extensive clinical trial data specific to each indication
• Mounjaro's approved indications are limited to type 2 diabetes and weight management
• PCOS is not listed as an approved indication on the medication's Summary of Product Characteristics
• Healthcare professionals retain the right to prescribe off-label when clinically appropriate
• Any off-label prescribing should be fully discussed with the patient

The Connection Between PCOS, Insulin Resistance and GLP-1 Medications

To understand why there is so much interest in Mounjaro for PCOS, we need to explore the underlying metabolic mechanisms that connect these conditions. Polycystic ovary syndrome is not simply a reproductive disorder; it is fundamentally a metabolic condition with hormonal manifestations. Research has consistently shown that up to 70% of women with PCOS have some degree of insulin resistance, regardless of their body weight.

Insulin resistance occurs when your body's cells become less responsive to insulin, the hormone that helps glucose enter cells for energy. In response, your pancreas produces more insulin to compensate, leading to elevated insulin levels in the blood. This hyperinsulinaemia has a direct effect on the ovaries, stimulating them to produce excess androgens (male hormones like testosterone), which in turn contributes to many of the symptoms women with PCOS experience, including irregular periods, acne, hirsutism, and difficulty conceiving.

Mounjaro works as a dual GIP and GLP-1 receptor agonist, which means it activates two different incretin hormone pathways simultaneously. This dual action helps to improve insulin sensitivity, reduce blood glucose levels, decrease appetite, and promote significant weight loss. The theoretical benefit for PCOS lies in this improvement of insulin sensitivity, which could potentially break the cycle of hyperinsulinaemia driving excess androgen production.

• Approximately 70% of women with PCOS have insulin resistance
• Hyperinsulinaemia directly stimulates ovarian androgen production
• Weight loss of just 5-10% can significantly improve PCOS symptoms
• GLP-1 medications improve insulin sensitivity through multiple mechanisms
• The metabolic benefits of tirzepatide may indirectly benefit PCOS symptoms

Off-Label Prescribing: When Mounjaro May Be Considered for PCOS

Off-label prescribing is a perfectly legitimate and common practice in medicine, occurring when a healthcare professional prescribes a medication for a condition or population that is not specifically listed in its marketing authorisation. In the context of PCOS and Mounjaro, this practice exists in a grey area that requires careful consideration by both prescribers and patients.

The General Medical Council guidance in the UK states that doctors may prescribe medications off-label when they believe it to be in the best interest of the patient, provided they can adequately explain their reasoning and the patient gives informed consent. For women with PCOS, this might occur when they also have significant obesity that qualifies them for weight management treatment, or when they have developed type 2 diabetes as a complication of their metabolic dysfunction.

It is important to understand that when Mounjaro is prescribed for weight management in a woman who happens to have PCOS, the primary indication remains weight loss, not PCOS treatment per se. However, the weight loss achieved may indirectly improve PCOS symptoms significantly. Studies have shown that losing just 5 to 10 percent of body weight can restore regular menstrual cycles in many women with PCOS, improve fertility, and reduce androgen levels.

Private clinics in the UK may be more willing to prescribe Mounjaro for women with PCOS who do not meet NHS criteria, but this comes with additional considerations including cost (which can be substantial), the need for ongoing monitoring, and the importance of choosing a reputable provider who will conduct proper assessments before prescribing.

• Off-label prescribing must be based on clinical judgement and patient benefit
• Informed consent is essential when medications are used outside licensed indications
• NHS prescribing for PCOS alone without obesity or diabetes is unlikely
• Private prescription may be an option but involves significant cost
• Any weight loss achieved can independently improve PCOS symptoms

Clinical Evidence for Tirzepatide in PCOS Management

When evaluating any medication for a particular condition, we must examine the available clinical evidence. For tirzepatide and PCOS specifically, the evidence base is still in its early stages, though preliminary data and extrapolation from related conditions offer some cause for optimism.

The SURMOUNT clinical trial programme, which led to Mounjaro's approval for weight management, included women with a wide range of comorbidities, and subgroup analyses have shown that metabolic benefits extend across different patient populations. While these trials did not specifically recruit women with PCOS or analyse outcomes specific to that condition, the improvements in insulin sensitivity, weight loss, and metabolic markers are all relevant to PCOS pathophysiology.

Earlier research on other GLP-1 receptor agonists, such as liraglutide and semaglutide, has shown promising results in women with PCOS. Studies have demonstrated improvements in menstrual regularity, reductions in androgen levels, improvements in insulin sensitivity, and enhanced fertility outcomes. Given that tirzepatide has a dual mechanism (targeting both GIP and GLP-1 receptors) and produces greater weight loss than single-receptor agonists in clinical trials, it is reasonable to hypothesise that it may offer similar or superior benefits for women with PCOS.

Ongoing research is investigating these possibilities more directly. Several clinical trials are currently recruiting or in progress to evaluate tirzepatide specifically in women with PCOS, examining outcomes such as ovulation rates, androgen levels, metabolic parameters, and quality of life measures. Results from these studies will be crucial in determining whether tirzepatide might eventually receive regulatory approval for PCOS treatment.

• No large-scale trials have yet been completed specifically for tirzepatide in PCOS
• Evidence from other GLP-1 medications suggests potential benefits
• Metabolic improvements seen in weight management trials are relevant to PCOS
• Several PCOS-specific tirzepatide trials are currently underway
• Results from ongoing research will inform future regulatory decisions

Treatment Option	UK Approval Status for PCOS	Primary Mechanism	Key Benefits for PCOS	NHS Availability
Mounjaro (Tirzepatide)	Not approved for PCOS	Dual GIP/GLP-1 receptor agonist	Weight loss, improved insulin sensitivity	Only for licensed indications (T2D, weight management)
Metformin	Off-label but widely used	Reduces hepatic glucose production, improves insulin sensitivity	Menstrual regularity, reduced androgen levels, fertility improvement	Yes, commonly prescribed
Combined Oral Contraceptives	Approved for menstrual regulation	Suppresses ovarian androgen production, increases SHBG	Regular periods, reduced acne and hirsutism	Yes, widely available
Clomifene	Approved for fertility	Selective oestrogen receptor modulator	Induces ovulation for fertility purposes	Yes, through fertility services
Orlistat	Approved for weight management	Lipase inhibitor reducing fat absorption	Weight loss may improve PCOS symptoms	Yes, for qualifying patients
Wegovy (Semaglutide)	Not approved for PCOS	GLP-1 receptor agonist	Weight loss, improved insulin sensitivity	Only for weight management indication

NICE-Approved Treatments for PCOS in the UK

The National Institute for Health and Care Excellence provides clinical guidelines for the management of PCOS in the UK, and these guidelines form the foundation of NHS treatment pathways. Understanding these approved treatments is important for women considering their options, as they represent evidence-based approaches that have been thoroughly evaluated for safety and effectiveness.

Lifestyle modification remains the cornerstone of PCOS management, particularly for women who are overweight or obese. NICE recommends that all women with PCOS should be encouraged to make sustainable dietary changes and increase physical activity, with the goal of achieving even modest weight loss. This approach is supported by strong evidence showing that weight reduction improves insulin sensitivity, restores menstrual regularity, reduces androgen levels, and enhances fertility.

For women requiring pharmacological treatment, metformin is often the first medication considered, particularly for those with insulin resistance or who are struggling with weight management. While metformin is technically used off-label for PCOS (as it is licensed for diabetes), its use in this context is well-established and supported by clinical guidelines. Metformin can help restore ovulation, regulate menstrual cycles, and may have modest effects on weight.

Combined oral contraceptives are recommended for women not seeking pregnancy who want to regulate their periods and reduce symptoms such as acne and hirsutism. These medications suppress ovarian androgen production and increase sex hormone binding globulin, effectively reducing the amount of free testosterone in the circulation. For women trying to conceive, clomifene citrate or letrozole may be used to induce ovulation, with assisted reproductive technologies available for more complex cases.

• Lifestyle modification is first-line treatment for all women with PCOS
• Metformin is commonly used for insulin resistance and weight management
• Combined oral contraceptives address menstrual irregularity and hyperandrogenic symptoms
• Ovulation induction medications are available for fertility treatment
• Treatment should be individualised based on symptoms and patient goals

Future Developments and Ongoing Research

The landscape of PCOS treatment is evolving rapidly, with increasing recognition that this is a complex metabolic condition requiring targeted therapeutic approaches. The emergence of highly effective GLP-1 receptor agonists and dual agonists like tirzepatide has sparked considerable interest in their potential application for women with PCOS.

Clinical trials specifically examining tirzepatide in PCOS populations are currently underway in various countries, including some with UK sites. These studies are investigating whether the medication can improve specific PCOS outcomes beyond what would be expected from weight loss alone. Endpoints being examined include ovulation rates, androgen levels, menstrual regularity, metabolic parameters, and fertility outcomes.

If ongoing research demonstrates that tirzepatide provides clinically meaningful benefits for PCOS beyond its weight loss effects, it is possible that the manufacturer could seek regulatory approval for this indication. Such approval would require substantial evidence from well-designed clinical trials and would need to demonstrate that benefits outweigh risks in this specific population. This process typically takes several years from trial completion to potential approval.

In the meantime, women with PCOS should work closely with their healthcare team to optimise management using currently available evidence-based treatments. The metabolic benefits of newer medications may become accessible through weight management or diabetes pathways for those who qualify, potentially providing indirect benefits for PCOS symptoms.

• Multiple clinical trials are investigating tirzepatide specifically for PCOS
• Trial endpoints include hormonal, metabolic, and reproductive outcomes
• Regulatory approval for a PCOS indication would require substantial evidence
• The timeline for potential approval is measured in years
• Current management should focus on established, evidence-based treatments

Key Takeaways

• Mounjaro is not currently approved by the MHRA for PCOS treatment in the UK and is only licensed for type 2 diabetes and chronic weight management
• Women with PCOS who also have obesity or type 2 diabetes may be able to access Mounjaro through these licensed indications, which could indirectly benefit their PCOS symptoms
• Off-label prescribing is possible but must be based on clinical judgement and informed consent, and is more likely to occur in private healthcare settings
• Evidence-based treatments currently recommended for PCOS include lifestyle modification, metformin, combined oral contraceptives, and fertility treatments where appropriate
• Ongoing clinical trials may eventually provide evidence to support regulatory approval of tirzepatide for PCOS, but this remains a future possibility rather than current reality

When to Seek Professional Advice

If you have PCOS and are interested in exploring whether Mounjaro or similar medications might be appropriate for your situation, the first step should always be a conversation with your GP or specialist. They can assess your individual circumstances, including your metabolic health, body mass index, and specific PCOS symptoms, to determine what treatment options might be suitable for you.

You should seek medical advice if you are experiencing new or worsening PCOS symptoms, if you have been unable to manage your weight despite lifestyle modifications, if your menstrual cycles are very irregular or absent, or if you are struggling with fertility. Additionally, if you have noticed signs of prediabetes or metabolic syndrome, such as increasing abdominal weight, darkening of skin in body creases, or abnormal blood test results, a comprehensive metabolic assessment would be beneficial.

For women considering obtaining Mounjaro through private clinics, it is essential to choose reputable providers who will conduct thorough assessments before prescribing. Be wary of any service that offers medication without proper evaluation, as this could put your health at risk. Your NHS GP can also provide guidance on the safety of any private treatment you are considering.

Scientific References

• NICE Guideline NG217: Polycystic ovary syndrome assessment and management
• Medicines and Healthcare products Regulatory Agency (MHRA)
• Royal College of Obstetricians and Gynaecologists: PCOS Guidelines

Frequently Asked Questions

Can my GP prescribe Mounjaro specifically for PCOS on the NHS?
No, GPs cannot prescribe Mounjaro on the NHS specifically for PCOS as it is not a licensed indication, though it may be prescribed if you meet criteria for type 2 diabetes or weight management.

Is there any evidence that Mounjaro helps with PCOS symptoms?
While there are no completed large-scale trials specifically for PCOS, evidence from related GLP-1 medications and the known metabolic benefits of tirzepatide suggest it may help through improvements in insulin sensitivity and weight loss.

How much does private Mounjaro treatment cost in the UK?
Private Mounjaro prescriptions typically cost between £150 to £300 per month depending on the dose, plus consultation fees, making it a significant ongoing expense for those not eligible for NHS treatment.

Will Mounjaro ever be approved for PCOS in the UK?
This depends on the results of ongoing clinical trials specifically investigating tirzepatide in PCOS populations; if evidence is strong enough, the manufacturer could apply for this indication, but this would likely take several years.